Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens
Since the discovery of penicillin by Alexander Fleming in 1929 as a therapeutic agent against staphylococci, β-lactam antibiotics (BLAs) remained the most successful antibiotic classes against the majority of bacterial strains, reaching a percentage of 65% of all medical prescriptions. Unfortunately...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/22/8527 |
| id |
doaj-888af3d4b24547fc92e52cc657ae365a |
|---|---|
| record_format |
Article |
| spelling |
doaj-888af3d4b24547fc92e52cc657ae365a2020-11-25T04:06:59ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-01218527852710.3390/ijms21228527Emerging Strategies to Combat β-Lactamase Producing ESKAPE PathogensCorneliu Ovidiu Vrancianu0Irina Gheorghe1Elena-Georgiana Dobre2Ilda Czobor Barbu3Roxana Elena Cristian4Marcela Popa5Sang Hee Lee6Carmen Limban7Ilinca Margareta Vlad8Mariana Carmen Chifiriuc9Microbiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaMicrobiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaMicrobiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaMicrobiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaMicrobiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaDepartment of Biological Sciences, Myongji University, 03674 Myongjiro, Yongin 449-728, Gyeonggido, KoreaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Traian Vuia no.6, 020956 Bucharest, RomaniaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, Traian Vuia no.6, 020956 Bucharest, RomaniaMicrobiology Immunology Department and The Research Institute of the University of Bucharest, Faculty of Biology, University of Bucharest, 020956 Bucharest, RomaniaSince the discovery of penicillin by Alexander Fleming in 1929 as a therapeutic agent against staphylococci, β-lactam antibiotics (BLAs) remained the most successful antibiotic classes against the majority of bacterial strains, reaching a percentage of 65% of all medical prescriptions. Unfortunately, the emergence and diversification of β-lactamases pose indefinite health issues, limiting the clinical effectiveness of all current BLAs. One solution is to develop β-lactamase inhibitors (BLIs) capable of restoring the activity of β-lactam drugs. In this review, we will briefly present the older and new BLAs classes, their mechanisms of action, and an update of the BLIs capable of restoring the activity of β-lactam drugs against ESKAPE (<i>Enterococcus </i>spp.<i>, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, </i>and<i> Enterobacter </i>spp.) pathogens. Subsequently, we will discuss several promising alternative approaches such as bacteriophages, antimicrobial peptides, nanoparticles, CRISPR (clustered regularly interspaced short palindromic repeats) cas technology, or vaccination developed to limit antimicrobial resistance in this endless fight against Gram-negative pathogens.https://www.mdpi.com/1422-0067/21/22/8527ESKAPEinhibitorsβ-lactamaseantimicrobial resistancevaccination |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Corneliu Ovidiu Vrancianu Irina Gheorghe Elena-Georgiana Dobre Ilda Czobor Barbu Roxana Elena Cristian Marcela Popa Sang Hee Lee Carmen Limban Ilinca Margareta Vlad Mariana Carmen Chifiriuc |
| spellingShingle |
Corneliu Ovidiu Vrancianu Irina Gheorghe Elena-Georgiana Dobre Ilda Czobor Barbu Roxana Elena Cristian Marcela Popa Sang Hee Lee Carmen Limban Ilinca Margareta Vlad Mariana Carmen Chifiriuc Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens International Journal of Molecular Sciences ESKAPE inhibitors β-lactamase antimicrobial resistance vaccination |
| author_facet |
Corneliu Ovidiu Vrancianu Irina Gheorghe Elena-Georgiana Dobre Ilda Czobor Barbu Roxana Elena Cristian Marcela Popa Sang Hee Lee Carmen Limban Ilinca Margareta Vlad Mariana Carmen Chifiriuc |
| author_sort |
Corneliu Ovidiu Vrancianu |
| title |
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens |
| title_short |
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens |
| title_full |
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens |
| title_fullStr |
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens |
| title_full_unstemmed |
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens |
| title_sort |
emerging strategies to combat β-lactamase producing eskape pathogens |
| publisher |
MDPI AG |
| series |
International Journal of Molecular Sciences |
| issn |
1661-6596 1422-0067 |
| publishDate |
2020-11-01 |
| description |
Since the discovery of penicillin by Alexander Fleming in 1929 as a therapeutic agent against staphylococci, β-lactam antibiotics (BLAs) remained the most successful antibiotic classes against the majority of bacterial strains, reaching a percentage of 65% of all medical prescriptions. Unfortunately, the emergence and diversification of β-lactamases pose indefinite health issues, limiting the clinical effectiveness of all current BLAs. One solution is to develop β-lactamase inhibitors (BLIs) capable of restoring the activity of β-lactam drugs. In this review, we will briefly present the older and new BLAs classes, their mechanisms of action, and an update of the BLIs capable of restoring the activity of β-lactam drugs against ESKAPE (<i>Enterococcus </i>spp.<i>, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, </i>and<i> Enterobacter </i>spp.) pathogens. Subsequently, we will discuss several promising alternative approaches such as bacteriophages, antimicrobial peptides, nanoparticles, CRISPR (clustered regularly interspaced short palindromic repeats) cas technology, or vaccination developed to limit antimicrobial resistance in this endless fight against Gram-negative pathogens. |
| topic |
ESKAPE inhibitors β-lactamase antimicrobial resistance vaccination |
| url |
https://www.mdpi.com/1422-0067/21/22/8527 |
| work_keys_str_mv |
AT corneliuovidiuvrancianu emergingstrategiestocombatblactamaseproducingeskapepathogens AT irinagheorghe emergingstrategiestocombatblactamaseproducingeskapepathogens AT elenageorgianadobre emergingstrategiestocombatblactamaseproducingeskapepathogens AT ildaczoborbarbu emergingstrategiestocombatblactamaseproducingeskapepathogens AT roxanaelenacristian emergingstrategiestocombatblactamaseproducingeskapepathogens AT marcelapopa emergingstrategiestocombatblactamaseproducingeskapepathogens AT sangheelee emergingstrategiestocombatblactamaseproducingeskapepathogens AT carmenlimban emergingstrategiestocombatblactamaseproducingeskapepathogens AT ilincamargaretavlad emergingstrategiestocombatblactamaseproducingeskapepathogens AT marianacarmenchifiriuc emergingstrategiestocombatblactamaseproducingeskapepathogens |
| _version_ |
1724430036877967360 |